Stoke Therapeutics, Inc. (STOK) income statement
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.69+0.28 (+1.06%)
Close on Nov 18, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -809.7%
- Net margin
- -753.6%
- Return on equity, FY2025
- -2.4%
Financial strength
- Current ratio
- 7.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 262.4%
Valuation
- P/E ratio
- –
- Price to sales
- 62.43
- Price to book
- 4.98
- Dividend yield
- –
See a number that looks wrong?